London, United Kingdom–(Newsfile Corp. – July 22, 2024) – Edison issues report on Baillie Gifford China Growth Trust (LSE: BGCG).
Baillie Gifford China Growth Trust’s investment objective is to produce long-term capital growth by investing predominantly in shares of Chinese companies. Performance is measured against the MSCI China All Shares Index. Baillie Gifford took over management of the trust from Witan Investment Services on 16 September 2020. Previously the trust aimed for capital and income growth from a diversified portfolio of investments in the Asia-Pacific region.
Click here to read the full report.
All reports published by Edison are available to download free of charge from its website www.edisongroup.com
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
enquiries@edisongroup.com
+44 (0)20 3077 5700
Connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
X www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/217289
Machine Learning with FLIT-SHAP Reveals Crucial Pollutant Interactions, Enhancing Toxicity Predictions and Environmental Health Decision-Making…
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship…
Seasoned pharmaceutical executive with extensive experience in high-growth life sciences companies joins NervGenLeadership appointment supports…
New findings highlight potential advantages of MIRA's novel oral ketamine analog for treating neurological and…
NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Omni-Biotic US is proud to…
NEWARK, CA / ACCESSWIRE / July 22, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or…